

2009

Mechanisms of evasion of the type i interferon antiviral response by flaviviruses

Michael S. Diamond
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Please let us know how this document benefits you.

Recommended Citation

Diamond, Michael S., "Mechanisms of evasion of the type i interferon antiviral response by flaviviruses." *Journal of Interferon & Cytokine Research*. 29, 9. 521-530. (2009).
https://digitalcommons.wustl.edu/open_access_pubs/2835

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.

Mechanisms of Evasion of the Type I Interferon Antiviral Response by Flaviviruses

Michael S. Diamond

Virus survival and the ability to cause disease in mammalian hosts depend on their ability to avoid recognition and control by the interferon signal transduction and effector pathways. Flaviviruses comprise a large family of nonsegmented positive sense enveloped cytoplasmic RNA viruses, many of which are globally important human pathogens. Although the mechanistic details are still being dissected, new insight has emerged as to how a flavivirus minimizes the antiviral activity of type I interferon (IFN) to establish productive and potentially lethal infection. This review will summarize our current understanding of how mammalian cells recognize flaviviruses to induce an inhibitory IFN response and the countermeasures this group of viruses has evolved to antagonize this response.

Introduction

FLAVIVIRUSES COMPRISE A GENUS of greater than 70 enveloped, positive sense RNA viruses and are distantly related to other Flaviviridae family members including hepatitis C virus (Lindenbach and Rice 2001). Many flavivirus infections are transmitted through the bite of an infected mosquito or tick, and have the potential to cause severe diseases in humans. Among the more common pathogenic flaviviruses in humans are Dengue (DENV), yellow fever (YFV), West Nile (WNV), Japanese encephalitis (JEV), Murray valley encephalitis (MVEV), Saint Louis encephalitis (SLEV), and tick-borne encephalitis (TBEV) viruses.

The ~11 kb flavivirus genome is transcribed as a single polyprotein and is cleaved by host and viral proteases into 3 structural and 7 nonstructural proteins. The structural proteins include a capsid protein (C) that binds viral RNA, a pre-membrane (prM) protein that blocks premature viral fusion, and an envelope (E) protein that mediates viral attachment, membrane fusion, and virion assembly (Mukhopadhyay and others 2005). The nonstructural proteins (NS1, NS2A, NS2B, NS3, NS4A NS4B, and NS5) regulate viral translation, transcription, and replication and also attenuate host antiviral responses. NS1 has cofactor activity for the viral replicase (Lindenbach and Rice 1997; Khromykh and others 1999), is secreted from infected cells (Flamand and others 1992; Flamand and others 1999), and antagonizes complement activation (Chung and others 2006). NS3 has protease, NTPase,

and helicase activities (Murthy and others 2000; Xu and others 2005) with NS2B serving as a required cofactor for NS3 protease activity (Yusof and others 2000). NS4A and NS4B are small hydrophobic proteins that lack conserved sequence motifs of known enzymes. Overexpression of NS4A induces membrane rearrangements that are observed in flavivirus-infected cells (Roosendaal and others 2006; Miller and others 2007) whereas NS4B, along with NS2A, colocalizes with replication complexes (Mackenzie and others 1998; Miller and others 2006). NS5 encodes the RNA-dependent RNA polymerase and a methyltransferase (Egloff and others 2002; Malet and others 2007; Yap and others 2007).

After binding to poorly characterized cell surface receptors on mammalian cells, internalization of flaviviruses occurs through receptor-mediated, clathrin-dependent endocytosis (Gollins and Porterfield 1986a; Kimura and others 1986; van der Schaar and others 2007; Acosta and others 2008; van der Schaar and others 2008), possibly in cholesterol-rich microdomains (Medigeshi and others 2008). After trafficking to Rab5- and/or Rab7-positive endosomes (Krishnan and others 2007; van der Schaar and others 2008), a low pH-catalyzed structural change in the E protein (Bressanelli and others 2004; Modis and others 2004) facilitates viral fusion and release of the infectious genomic RNA into the cytoplasm (Gollins Porterfield 1986b). Flavivirus RNA traffics to the rough endoplasmic reticulum (ER) where it is translated, and serves as a template for a negative strand RNA

intermediate that primes synthesis of positive strand viral RNA containing an N⁷-methyl-guanosine cap but lacking a poly-A tail (Lindenbach and Rice 2001; Brinton 2002). Flavivirus positive strand RNA is either packaged within progeny virion or used to translate additional viral proteins. Flaviviruses assemble at and bud into the ER to form immature particles that display the prM protein. Following transport through the trans-Golgi network, furin-mediated cleavage of prM to M generates mature, infectious virions that are released by exocytosis (Guirakhoo and others 1991; Elshuber and others 2003).

Recognition of flaviviruses by host sensors

Interferon (IFN) responses are an initial and essential host defense program against many viruses, including flaviviruses. IFNs are produced during the earliest stages of viral infection after recognition of pathogen-associated molecular patterns (PAMP) by specific pathogen recognition receptors (PRR). In mammalian cells, the host detects and responds to infection by flaviviruses by primarily recognizing viral RNA through several distinct PRR including the cell surface and endosomal RNA sensors Toll-like receptors 3 and 7 (TLR3 and TLR7), and the cytoplasmic RNA sensors retinoic acid-inducible gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) (Fig. 1A and 1B). Binding of single- and/or double-stranded viral RNA to these PRR results in downstream activation of transcription factors, such as interferon regulatory factors 3 and 7 (IRF-3 and IRF-7) and NF- κ B, and induction of IFN- α and - β . Secretion of IFNs followed by engagement of the IFN- α receptor (IFNAR) in an autocrine and paracrine fashion activates JAK-STAT-dependent and -independent signal transduction cascades (Stark and others 1998; Li and others 2007) that induce the expression of hundreds of interferon-stimulated genes (ISGs), a subset of which likely have antiviral activity against flaviviruses (Fig. 2).

Recent studies suggest that RIG-I and MDA5 contribute to the induction of host IFN and antiviral response to flaviviruses. Murine embryonic fibroblasts (MEF) deficient in RIG-I and MDA5 demonstrate decreased IRF-3 activation, delayed induction of host interferon and ISG responses, and augmented WNV and DENV replication (Fredericksen and others 2004; Fredericksen and Gale 2006; Fredericksen and others 2008; Loo and others 2008). In these cells, RIG-I appeared to prime the early IFN response whereas MDA5 has a more significant role in a second phase of IFN-dependent gene expression that occurs later in the course of infection (Fredericksen and others 2008). A genetic deficiency of IPS-1 (also known as Cardif, MAVS, or VISA), an essential RIG-I and MDA5 adaptor molecule that is anchored to the outer leaflet of the mitochondria, completely disabled the innate IFN response to WNV (Fredericksen and others 2008). However, MDA5 may be less essential for recognition of flaviviruses in some myeloid cell types, as IFN production by MDA5^{-/-} myeloid dendritic cells remains largely intact after WNV infection (Gitlin and others 2006), and a deficiency of MDA5 in mice did not affect survival after JEV (Kato and others 2006). Consistent with this, JEV and DENV induce the host type I IFN response through a mechanism involving RIG-I/IRF-3 and NF- κ B (Chang and others 2006).

Despite the compelling data from MEF suggesting that RIG-I and likely MDA5 recognize WNV RNA and induce type I IFN responses (Fredericksen and others 2008), IFN- α

and - β production in mice appears largely independent of the downstream transcription factor IRF-3 (Bourne and others 2007; Daffis and others 2007). Individual cell types (myeloid, fibroblast, and neuronal) use distinct IRF-3 responses to protect against WNV infection through both IFN-dependent and -independent pathways (Daffis and others 2007). In cells that generate robust IFN responses after WNV infection in the absence of IRF-3, it is likely that alternate sets of PRR and transcriptional regulators are used.

TLR3, which is expressed on the surface of fibroblasts and in the endosomes of myeloid cells, promotes IRF-3 phosphorylation after binding double-stranded viral RNA through a complex signaling cascade that includes recruitment of TRIF and activation of the kinases TBK1 and IKK- ϵ (Matsumoto and others 2004; Schroder and Bowie 2005). Initial studies with TRIF-deficient MEF suggested that TLR3 may be dispensable for recognition of flaviviruses in cells (Fredericksen and Gale 2006). Indeed, TLR3^{-/-} mice injected by an intraperitoneal route paradoxically showed decreased lethality despite higher peripheral viral titers, presumably because of blunted cytokine responses (eg, TNF- α) that normally facilitates WNV entry into the CNS (Wang and others 2004). Subsequent studies with TLR3^{-/-} mice and a different North American WNV strain have shown increased viral burden in the brain and enhanced lethality (Daffis and others 2008a), as might be anticipated for a PRR that triggers a protective host immune response. *Ex vivo* and *in vivo* experiments suggest a cell-specific role of TLR3 as it protects against WNV largely by restricting replication in neurons.

TLR7 is an endosomal PRR that detects guanosine- and uridine-rich single-stranded RNA (Diebold and others 2004; Heil and others 2004) and activates IRF-7 via the Myd88 adaptor molecule. IRF-7 was identified as a primary regulator of antiviral gene induction after YFV infection (Gaucher and others 2008), with some of this activation occurring through TLR7 recognition of viral RNA (Querec and others 2006). Similarly, DENV stimulates IFN production in plasmacytoid dendritic cells in a TLR7-dependent manner after virus uncoating (Wang and others 2006). The antiviral IFN- α response against WNV is primarily mediated by IRF-7, and at least some of this signal is likely attributed to recognition of viral RNA by TLR7 (Daffis and others 2008b). An independent role for dsRNA-dependent protein kinase R (PKR) in the early induction of IFN in fibroblasts after WNV infection has also been observed (Gilfooy and Mason 2007).

IFN-mediated control of flaviviruses

Type I IFN is an important innate immune system regulator of viral infections (reviewed in Platanius and others (1996); Platanius (2005)). IFN- α and - β are secreted by many cell types following virus infection and induce an antiviral state by up-regulating genes with both direct and indirect antiviral functions. Type I IFN also primes adaptive immune responses through stimulation of dendritic cells, activation of B and T cells, and by preventing death of recently activated T cells (Stetson and Medzhitov 2006; Purtha and others 2008). Pretreatment of cells with IFN- α / β inhibits flavivirus replication *in vitro* (Diamond and others 2000; Anderson and Rahal 2002; Lin and others 2004; Best and others 2005; Samuel and others 2006), but treatment after infection is much less effective (Diamond and others 2000; Anderson and Rahal 2002; Crance and others




FIG. 1. Detection of flavivirus RNA by pathogen recognition receptors (PRRs) and mechanisms of viral evasion. (A) Cytoplasmic PRR and signaling cascade. Infection by flaviviruses produces dsRNA replication intermediates within the cytoplasm that display motifs recognized by the RIG-I and MDA5 helicases. Binding of viral RNA promotes an interaction with IPS-1 that results in recruitment of signaling proteins (NEMO and TRAF3) that activate IRF-3 and NF-κB. These transcription factors translocate to the nucleus and bind to the promoter region of the IFN-β gene leading to transcription and translation. (Continued)

2003; Samuel and Diamond 2005). Although flaviviruses can antagonize IFN-induced responses after infection (see below), IFN still restricts replication and spread *in vivo*. Mice lacking the type I IFN receptor (IFNAR^{-/-}) show markedly enhanced lethality and replication after infection with WNV (Samuel and Diamond 2005; Keller and others 2006), DENV (Shresta and others 2004), and MVEV (Lobigs and others 2003). Enhanced infection occurred in normally

resistant cell populations and tissues after flavivirus infection of IFNAR^{-/-} mice, suggesting that IFN acts in part, to restrict viral tropism. The importance of type I IFN in restricting flavivirus infection has been confirmed in therapeutic disease models. Pretreatment of mice with IFN-α or inducers of IFN-α attenuates infection by SLEV, WNV, YFV, and Modoc viruses in mice and hamsters (Stephen and others 1977; Brooks and Phillpotts 1999; Leyssen and others




FIG. 1. (Continued) **(B)** Toll-like receptor (TLR) signaling cascade. In some cells, the transmembrane pathogen recognition receptors (PRRs) TLR3 and TLR7/8 in endosomes recognize dsRNA and ssRNA motifs leading to recruitment of cytoplasmic adaptor molecules (TRIF and MyD88, respectively), which initiates signaling cascades (via IKK- ϵ , TBK1, RIP-1, and IRAK4) that activate IRF-3, IRF-7, and NF- κ B, resulting in IFN- β gene transcription. Mechanisms of evasion by flaviviruses are believed to include the following: (1) a delay in recognition of West Nile virus (WNV) RNA by RIG-I; (2) impairment of RIP-1 signaling by high mannose carbohydrates on the structural E protein; (3) attenuation of TLR3 signaling by the NS1 protein; and (4) reduction in IFN- β gene transcription by the viral NS2A protein. Cartoon is modeled after published images (Gale and Foy 2005; Best and others 2006; Keller and others 2007; Takeuchi and Akira 2007).

2001; Leyssen and others 2003; Morrey and others 2004; Julander and others 2007).

Secretion of IFN initiates a complex signal transduction cascade (Fig. 2) that results in the induction of a large

number of proteins with antiviral, immunomodulatory, and cell death-promoting functions (Stark and others 1998). Binding of IFN- α and - β to their cognate common receptor (IFNAR1/IFNAR2 heterodimer) activates intracellular JAK1




FIG. 2. Type I interferon (IFN) signaling and mechanisms of disruption by flaviviruses. Secretion of IFN by a flavivirus-infected cell results in autocrine and paracrine signaling through the heterodimeric IFN- $\alpha\beta$ receptor (IFNAR). Binding by IFN results in activation and tyrosine phosphorylation of JAK family members (JAK1 and Tyk2) and the cytoplasmic tail of the IFN- $\alpha\beta$ R. This promotes recruitment of the STAT1 and STAT2, which themselves become phosphorylated by the JAKs. Phosphorylated STAT1 and STAT2 proteins heterodimerize, associate with IRF-9, and translocate to the nucleus, where they bind ISRE sequences to induce expression of hundreds of ISG. Mechanisms of evasion by flaviviruses are believed to include the following: blockade of phosphorylation of (1) Tyk2 and (2) JAK1 by NS5; (3) activation of a phosphotyrosine phosphatase by NS5; (4) reduction in STAT2 gene and protein expression; attenuation of STAT signaling by (5) NS4B and (6) NS5; and (7) down-regulation of the IFNAR through virus-induced redistribution of cellular cholesterol. Cartoon is modeled after published images (Gale and Foy 2005; Keller and others 2007).

and Tyk2 Janus kinases, which phosphorylate tyrosine residues on the cytoplasmic tail of the IFNAR. These phosphorylated tyrosine residues function as recruitment sites for the cytoplasmic proteins, STAT1 and STAT2, which themselves become phosphorylated by the JAKs. Phosphorylated STAT1 and STAT2 proteins heterodimerize, associate with IRF-9, and translocate to the nucleus, where they transcriptionally activate specific DNA promoter sequences to induce expression of hundreds of ISG mRNA.

Recent studies have begun to define the specific IFN-induced antiviral effector mechanisms that limit flavivirus infection. dsRNA-dependent protein kinase (PKR) and 2'-5'-oligoadenylate synthase (OAS) proteins mediate intrinsic cell resistance to WNV. PKR is activated by binding dsRNA and phosphorylates the eukaryotic translation initiation factor 2 (eIF2- α) resulting in attenuation of protein synthesis

(Meurs and others 1992). RNase L is activated by 2'-5'-linked oligoadenylates that are synthesized by OAS enzymes. RNase L functions as an endoribonuclease that cleaves viral and host RNA (Zhou and others 1993; Zhou and others 1997). RNase L^{-/-} MEF and PKR^{-/-} × RNase L^{-/-} macrophages supported increased WNV replication *in vitro* (Samuel and others 2006; Scherbik and others 2006). Moreover, mice deficient in both PKR and RNase L showed increased lethality following WNV infection, with higher viral loads in peripheral tissues at early time points after infection (Samuel and others 2006). The antiviral mechanism of action of PKR against WNV remains unclear: it could exert direct antiviral effects due to inhibition of viral translation, or function indirectly by inducing IFN (Gilfoy and Mason 2007). Interestingly, at least in MEF, a similar antiviral effect of PKR and RNase L on DENV infection was not observed (Diamond and Harris 2001).

Although susceptibility to flaviviruses in mice has been mapped to a mutation in the *Oas* gene 1b, resulting in the expression of a truncated OAS isoform (Mashimo and others 2002; Perelygin and others 2002), the mechanism of control by this gene appears independent of RNase L (Samuel and others 2006; Scherbik and others 2006) and the type I IFN-signaling pathway (Brinton and others 1982).

Antagonism of the IFN response by flaviviruses

Flaviviruses have evolved specific strategies to avoid and/or attenuate induction of IFN and its effector responses (Figs. 1 and 2). Indeed, in cell culture flaviviruses are largely resistant to the antiviral effects of IFN once infection is established (Diamond and others 2000; Anderson and Rahal 2002). This may explain in part, the relatively modest therapeutic window for IFN- α administration that has been observed clinically in animal models or humans infected with JEV, SLEV, and WNV (Brooks and Phillpotts 1999; Solomon and others 2003; Rahal and others 2004; Chan-Tack and Forrest 2005; Kalil and others 2005). Experiments by several groups have demonstrated that individual flaviviruses attenuate IFN signaling at distinct steps in the cascade.

Inhibition of IFN- β gene induction. To date, 3 independent mechanisms have been proposed by which flaviviruses minimize the induction of IFN- β .

- a. IFN- β gene transcription. Studies with Kunjin (KUNV) virus, a less pathogenic lineage I WNV variant, have identified the nonstructural protein NS2A as an inhibitor of IFN- β gene transcription (Liu and others 2004; Liu and others 2006). Transgenic expression of NS2A was sufficient to suppress IFN- β transcription in Semliki Forest virus-infected cells. Incorporation of an A30P mutation of NS2A into a KUNV genome results in a virus that elicits more rapid and sustained synthesis of type I IFN; infection of this mutant virus *in vitro* and *in vivo* was highly attenuated. Nonetheless, the exact cellular target of NS2A and its mechanism of inhibition remain unknown.
- b. PRR detection. Highly pathogenic WNV strains evade IRF-3-dependent recognition pathways without actively antagonizing the host defense signaling pathways (Fredericksen and Gale 2006). Indeed, WNV replication did not alter the ability of Sendai virus to activate IRF-3. Thus, virulent WNV strains appear to delay activation of PRR, such as RIG-I, through uncertain mechanisms to provide the virus with a kinetic advantage in the infected cell to elude host detection during replication at early times after infection (Keller and others 2007). In contrast, less pathogenic strains of WNV induced greater levels of IFN at early time points (Keller and others 2006).
- c. TLR3-dependent responses. Activation of IRF-3 and stimulation of IFN- β transcription in response to dsRNA (poly (I:C)) are inhibited in HeLa cells infected with WNV or stably propagating a subgenomic replicon (Scholle and Mason 2005). The viral NS1 protein may mediate a part of this inhibitory effect as expression of WNV NS1 inhibited TLR3-induced transcriptional activation of the IFN- β and IL-6 transcription and NF- κ B promoter activity (Wilson and others 2008). Alternatively, the high mannose carbohydrates on the viral E protein may independently block the production of IFN- β , IL-6, and TNF- α that is induced by dsRNA in macrophages. This effect was not directly

dependent on TLR3 or its adaptor molecule TRIF but instead occurred downstream at the level of the signaling intermediate and NF- κ B activator, receptor-interacting protein (RIP)-1 (Arjona and others 2007). Based on studies with macrophages from different age cohorts, this E protein inhibitory pathway may be dysregulated in elderly humans, leading to a pathogenic cytokine response (Kong and others 2008). Although the mechanistic basis for how specific forms of the E protein alter antiviral signaling programs remains uncertain, glycosylated E proteins can bind to and potentially signal through multiple cell surface lectins including the mannose receptor (Miller and others 2008) and CLEC5a (Chen and others 2008).

Impaired IFNAR pathway signaling. In addition to antagonizing induction of IFN- β gene responses, several flaviviruses target the JAK-STAT signaling pathway for evasion (Best and others 2006; Robertson and others 2009) to prevent the induction of antiviral ISG with possible antiviral activity. Thus, even when type I IFN is produced, it may not achieve the same inhibitory effect because of attenuated signaling capacity. As the nonstructural proteins NS2A, NS3, NS4A, NS4B, and NS5 mediate many of the viral evasion mechanisms described below, these countermeasures are largely intrinsic to infected cells. One caveat to the majority of the studies below is that the conclusions were derived from experiments in transformed cells. Even with these attenuating mechanisms, in primary macrophages and dendritic cells, flaviviruses such as WNV remain potent ISG inducers (Daffis and others 2007, 2008a, 2008b).

- a. Phosphorylation of JAKs. Studies with the tick-borne Langat virus (LGV) and WNV have shown interference with phosphorylation of both JAK1 and Tyk2 (Best and others 2005; Guo and others 2005). A slight variation on this theme was observed with JEV, which showed complete inhibition of phosphorylation of Tyk2 with little effect on JAK1 phosphorylation (Lin and others 2004). Expression of a subgenomic replicon or infection of cells with DENV also inhibited Tyk2 phosphorylation and had no effect on IFNAR expression (Ho and others 2005; Jones and others 2005). However, there may be cell- or virus-specific effects as JEV also inhibits STAT1 and STAT2 activation in the setting of normal levels of Tyk2 phosphorylation (Lin and others 2008).
- b. STAT gene expression. DENV has been reported to antagonize IFN function by reducing STAT2 expression (Jones and others 2005). Cell lines that stably propagated subgenomic DENV replicons were resistant to the antiviral effects of IFN- α , had reduced levels of STAT2, and blunted ISG responses. Accordingly, IFN- α but not IFN- γ responses were blocked in these cells.
- c. Cholesterol redistribution. Recent studies have shown that flavivirus infection can actively promote relocalization of cholesterol to intracellular membranous sites of replication. This redistribution diminishes the formation of cholesterol-rich lipid rafts in the plasma membrane and attenuates the IFN antiviral signaling response (Mackenzie and others 2007).
- d. NS proteins as specific IFN antagonists. The observation that flaviviruses antagonize IFN-signaling responses has prompted several groups to identify the viral determinants and mechanisms that mediate this process. Initial

transgenic expression studies in A549 cells with DENV showed that NS2A, NS4A, or NS4B enhanced replication of an IFN-sensitive virus by blocking nuclear localization of STAT1 (Munoz-Jordan and others 2003). Subsequent experiments showed that NS4B of DENV, WNV, and YFV partially block STAT1 activation and ISG induction (Munoz-Jordan and others 2005). Mutagenesis studies have identified a sequence determinant on WNV NS4B (E22/K24) that controls IFN resistance in cells expressing subgenomic replicons, although in cells expressing infectious virus this NS4B determinant did not regulate the IFN response, suggesting an independent role for structural genes (Evans and Seeger 2007).

NS5 has been reported as the primary nonstructural protein responsible for attenuating JAK-STAT signaling after LGV, JEV, and TBEV infection (Best and others 2005; Lin and others 2006; Werme and others 2008). However, the mechanism of NS5 inhibition may have virus-specific characteristics. For TBEV, a sequence in the methyltransferase domain of NS5 binds the PDZ protein scribble to inhibit JAK-STAT signaling (Werme and others 2008). For JEV, the N-terminal 83 residues of NS5 inhibit JAK-STAT signaling through a protein-tyrosine phosphatase-dependent mechanism (Lin and others 2006). Finally, for LGV, the JAK-STAT inhibitory domain was mapped to sites within the RNA-dependent RNA polymerase domain (Park and others 2007).

Impaired IFN effector functions. Although flaviviruses devote a significant segment of their genome to inhibiting JAK-STAT signaling, they may also target individual downstream antiviral effector molecules. Viperin is a candidate antiviral ISG with inhibitory activity against hepatitis C, influenza, HIV, and Sindbis viruses (Rivieccio and others 2006; Wang and others 2007; Zhang and others 2007; Jiang and others 2008), possibly because of its ability to alter lipid raft formation (Wang and others 2007). JEV, however, counteracts the antiviral activity of viperin by promoting rapid proteasome-dependent degradation (Chan and others 2008). The mechanism of this inhibition remains unclear as transfection of individual JEV proteins failed to recapitulate the phenotype suggesting a combined effect of viral proteins or replication is required.

Summary

The use of animal and cell culture models has fostered an improved understanding of the balance between flavivirus pathogenesis and immune control. IFN responses limit infection flaviviruses and not surprisingly, as a group, these successful mammalian pathogens have developed countermeasures to facilitate infectivity and transmission. In the last 5 years, the field has learned the identity of specific PRR that detect entry and infection by flaviviruses and initiate a protective IFN response, and which viral proteins allow evasion of the response. The next decade will likely provide us with insight into mechanisms as several key questions remain unanswered. These include (a) identification of the specific PAMP on flaviviruses that are recognized by PRR. Experiments with hepatitis C virus have identified homopolyuridine and homopolyriboadenine motifs as substrates for RIG-I (Saito and others 2008). What additional recognition motifs will there be for flaviviruses, which lack these sequences and yet, are still recognized RIG-I?; (b) What are

the particular ISG that mediate antiviral effector functions against flaviviruses? Although some molecules (eg, PKR and RNase L) have been identified, they do not account for the majority of inhibitory activity that is generated after exogenous IFN treatment or endogenous IFN induction in most cells? What ISG have key inhibitory functions against flaviviruses? Will IFN-induced microRNA that regulate transcription of host genes essential for viral replication explain some of the inhibitory effect (Pedersen and others 2007; Mahajan and others 2009)?; (c) How do flavivirus proteins disable the cellular IFN induction and signaling response? What are the precise host target proteins and the molecular and structural basis of the antagonism?; and (d) Are virulence determinants that antagonize specific IFN induction or effector pathways a quality that defines highly virulent and disease causing flavivirus strains? As these basic mechanisms are explored and characterized, the field undoubtedly will gain insight into fundamental cellular responses as well mechanisms of viral pathogenesis. It is this information that may facilitate the design of novel vaccine or targeted therapeutic strategies and enhance our understanding of how pathogens of all types cause disease.

Acknowledgments

M.S.D. would like to thank T. Pierson, S. Daffis, and K. Szretter for critical comments and suggestions on the manuscript and M. Gale for stimulating discussions.

References

- Acosta EG, Castilla V, Damonte EB. 2008. Functional entry of dengue virus into *Aedes albopictus* mosquito cells is dependent on clathrin-mediated endocytosis. *J Gen Virol* 89(Pt 2):474–484.
- Anderson JF, Rahal JJ. 2002. Efficacy of interferon alpha-2b and ribavirin against West Nile virus *in vitro*. *Emerg Infect Dis* 8(1):107–108.
- Arjona A, Ledizet M, Anthony K, Bonafe N, Modis Y, Town T, Fikrig E. 2007. West Nile Virus Envelope Protein Inhibits dsRNA-Induced Innate Immune Responses. *J Immunol* 179(12):8403–8409.
- Best SM, Mitzel DN, Bloom ME. 2006. Action and reaction: the arthropod-borne flaviviruses and host interferon response. *Future Virol* 1(4):447–459.
- Best SM, Morris KL, Shannon JG, Robertson SJ, Mitzel DN, Park GS, Boer E, Wolfenbarger JB, Bloom ME. 2005. Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist. *J Virol* 79(20):12828–12839.
- Bourne N, Scholle F, Silva MC, Rossi SL, Dewsbury N, Judy B, De Aguiar JB, Leon MA, Estes DM, Fayzulin R, Mason PW. 2007. Early production of type I interferon during West Nile virus infection: role for lymphoid tissues in IRF3-independent interferon production. *J Virol* 81:9100–9108.
- Bressanelli S, Stiasny K, Allison SL, Stura EA, Duquerroy S, Lescar J, Heinz FX, Rey FA. 2004. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. *EMBO J* 23(4):728–738.
- Brinton MA. 2002. The molecular biology of West Nile Virus: a new invader of the western hemisphere. *Annu Rev Microbiol* 56:371–402.
- Brinton MA, Arnheiter H, Haller O. 1982. Interferon independence of genetically controlled resistance to flaviviruses. *Infect Immun* 36(1):284–288.
- Brooks TJ, Philippotts RJ. 1999. Interferon-alpha protects mice against lethal infection with St Louis encephalitis virus delivered by the aerosol and subcutaneous routes. *Antiviral Res* 41(1):57–64.

- Chan YL, Chang TH, Liao CL, Lin YL. 2008. The cellular antiviral protein viperin is attenuated by proteasome-mediated protein degradation in Japanese encephalitis virus-infected cells. *J Virol* 82(21):10455–10464.
- Chan-Tack KM, Forrest G. 2005. Failure of interferon alpha-2b in a patient with West Nile virus meningoencephalitis and acute flaccid paralysis. *Scand J Infect Dis* 37(11–12):944–946.
- Chang TH, Liao CL, Lin YL. 2006. Flavivirus induces interferon-beta gene expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-dependent NF-kappaB activation. *Microbes Infect* 8(1):157–171.
- Chen ST, Lin YL, Huang MT, Wu MF, Cheng SC, Lei HY, Lee CK, Chiou TW, Wong CH, Hsieh SL. 2008. CLEC5A is critical for dengue-virus-induced lethal disease. *Nature* 453(7195):672–676.
- Chung KM, Liszewski MK, Nybakken G, Davis AE, Townsend RR, Fremont DH, Atkinson JP, Diamond MS. 2006. West Nile virus non-structural protein NS1 inhibits complement activation by binding the regulatory protein factor H. *Proc Natl Acad Sci USA* 103(50):19111–19116.
- Crance JM, Scaramozzino N, Jouan A, Garin D. 2003. Interferon, ribavirin, 6-azauridine and glycyrrhizin: antiviral compounds active against pathogenic flaviviruses. *Antiviral Res* 58(1):73–79.
- Daffis S, Samuel MA, Keller BC, Gale M, Jr, Diamond MS. 2007. Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and independent mechanisms. *PLoS Pathog* 3(7):e106.
- Daffis S, Samuel MA, Suthar MS, Gale M, Jr, Diamond MS. 2008a. Toll-like receptor 3 has a protective role against West Nile virus infection. *J Virol* 82(21):10349–10358.
- Daffis S, Samuel MA, Suthar MS, Keller BC, Gale M, Jr, Diamond MS. 2008b. Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. *J Virol* 82(17):8465–8475.
- Diamond MS, Harris E. 2001. Interferon inhibits dengue virus infection by preventing translation of viral RNA through a PKR-independent mechanism. *Virology* 289(2):297–311.
- Diamond MS, Roberts T, Edgil D, Lu B, Ernst J, Harris E. 2000. Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. *J Virol* 74(11):4957–4966.
- Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. 2004. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science* 303(5663):1529–1531.
- Egloff MP, Benarroch D, Selisko B, Romette JL, Canard B. 2002. An RNA cap (nucleoside-2'-O)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. *EMBO J* 21(11):2757–2768.
- Elshuber S, Allison SL, Heinz FX, Mandl CW. 2003. Cleavage of protein prM is necessary for infection of BHK-21 cells by tick-borne encephalitis virus. *J Gen Virol* 84(Pt 1):183–191.
- Evans JD, Seeger C. 2007. Differential Effects of Mutations in NS4B on WNV Replication and Inhibition of Interferon Signaling. *J Virol* 81:11809–11816.
- Flamand M, Deubel V, Girard M. 1992. Expression and secretion of Japanese encephalitis virus nonstructural protein NS1 by insect cells using a recombinant baculovirus. *Virology* 191(2):826–836.
- Flamand M, Megret F, Mathieu M, Lepault J, Rey FA, Deubel V. 1999. Dengue virus type 1 nonstructural glycoprotein NS1 is secreted from mammalian cells as a soluble hexamer in a glycosylation-dependent fashion. *J Virol* 73(7):6104–6110.
- Fredericksen BL, Gale M, Jr. 2006. West Nile virus evades activation of interferon regulatory factor 3 through RIG-I-dependent and -independent pathways without antagonizing host defense signaling. *J Virol* 80(6):2913–2923.
- Fredericksen BL, Keller BC, Fornek J, Katze MG, Gale M, Jr. 2008. Establishment and maintenance of the innate antiviral response to West Nile virus involves both RIG-I and MDA5 signaling through IPS-1. *J Virol* 82(2):609–616.
- Fredericksen BL, Smith M, Katze MG, Shi PY, Gale M. 2004. The host response to West Nile virus infection limits spread through the activation of the interferon regulatory factor 3 pathway. *J Virol* 78(14):7737–7747.
- Gale M, Jr, Foy EM. 2005. Evasion of intracellular host defence by hepatitis C virus. *Nature* 436(7053):939–945.
- Gaucher D, Therrien R, Kettaf N, Angermann BR, Boucher G, Filali-Mouhim A, Moser JM, Mehta RS, Drake DR, III, Castro E, Akondy R, Rinfret A, Yassine-Diab B, Said EA, Chouikh Y, Cameron MJ, Clum R, Kelvin D, Somogyi R, Greller LD, Balderas RS, Wilkinson P, Pantaleo G, Tartaglia J, Haddad EK, Sekaly RP. 2008. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. *J Exp Med* 205(13):3119–3131.
- Gilfoyl FD, Mason PW. 2007. West Nile virus-induced IFN production is mediated by the double-stranded RNA-dependent protein kinase, PKR. *J Virol* 81(20):11148–11158.
- Gitlin L, Barchet W, Gilfillan S, Cella M, Beutler B, Flavell RA, Diamond MS, Colonna M. 2006. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. *Proc Natl Acad Sci USA* 103(22):8459–8464.
- Gollins S, Porterfield J. 1986a. The uncoating and infectivity of the flavivirus West Nile on interaction with cells: effects of pH and ammonium chloride. *J Gen Virol* 67(Pt 9):1941–1950.
- Gollins SW, Porterfield JS. 1986b. pH-dependent fusion between the flavivirus West Nile and liposomal model membranes. *J Gen Virol* 67(Pt 1):157–166.
- Guirakhoo F, Heinz FX, Mandl CW, Holzmann H, Kunz C. 1991. Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions. *J Gen Virol* 72(Pt 6):1323–1329.
- Guo JT, Hayashi J, Seeger C. 2005. West Nile virus inhibits the signal transduction pathway of alpha interferon. *J Virol* 79(3):1343–1350.
- Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. 2004. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. *Science* 303(5663):1526–1529.
- Ho LJ, Hung LF, Weng CY, Wu WL, Chou P, Lin YL, Chang DM, Tai TY, Lai JH. 2005. Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. *J Immunol* 174(12):8163–8172.
- Jiang D, Guo H, Xu C, Chang J, Gu B, Wang L, Block TM, Guo JT. 2008. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. *J Virol* 82(4):1665–1678.
- Jones M, Davidson A, Hibbert L, Gruenewald P, Schlaak J, Ball S, Foster GR, Jacobs M. 2005. Dengue virus inhibits alpha interferon signaling by reducing STAT2 expression. *J Virol* 79(9):5414–5420.
- Julander JG, Morrey JD, Blatt LM, Shafer K, Sidwell RW. 2007. Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. *Antiviral Res* 73(2):140–146.
- Kalil AC, Devetten MP, Singh S, Lesiak B, Poage DP, Bargenquast K, Fayad P, Freifeld AG. 2005. Use of interferon-alpha in patients with West Nile encephalitis: report of 2 cases. *Clin Infect Dis* 40(5):764–766.
- Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsumimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* 441(7089):101–105.
- Keller BC, Fredericksen BL, Samuel MA, Mock RE, Mason PW, Diamond MS, Gale M, Jr. 2006. Resistance to alpha/beta interferon is a determinant of West Nile virus replication fitness and virulence. *J Virol* 80(19):9424–9434.
- Keller BC, Johnson CL, Erickson AK, Gale M, Jr. 2007. Innate immune evasion by hepatitis C virus and West Nile virus. *Cytokine Growth Factor Rev* 18(5–6):535–544.
- Khromykh AA, Sedlak PL, Guyatt KJ, Hall RA, Westaway EG. 1999. Efficient trans-complementation of the flavivirus kunjin

- NS5 protein but not of the NS1 protein requires its coexpression with other components of the viral replicase. *J Virol* 73(12):10272–10280.
- Kimura T, Gollins SW, Porterfield JS. 1986. The effect of pH on the early interaction of West Nile virus with P388D1 cells. *J Gen Virol* 67(Pt 11):2423–2433.
- Kong KF, Delroux K, Wang X, Qian F, Arjona A, Malawista SE, Fikrig E, Montgomery RR. 2008. Dysregulation of TLR3 impairs the innate immune response to West Nile virus in the elderly. *J Virol* 82(15):7613–7623.
- Krishnan MN, Sukumaran B, Pal U, Agaisse H, Murray JL, Hodge TW, Fikrig E. 2007. Rab 5 is required for the cellular entry of dengue and West Nile viruses. *J Virol* 81(9):4881–4885.
- Leyssen P, Drosten C, Paning M, Charlier N, Paeshuysse J, De Clercq E, Neyts J. 2003. Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. *Antimicrob Agents Chemother* 47(2):777–782.
- Leyssen P, Van Lommel A, Drosten C, Schmitz H, De Clercq E, Neyts J. 2001. A novel model for the study of the therapy of flavivirus infections using the modoc virus. *Virology* 279(1):27–37.
- Li H, Gade P, Xiao W, Kalvakolanu DV. 2007. The interferon signaling network and transcription factor C/EBP-beta. *Cell Mol Immunol* 4(6):407–418.
- Lin CW, Cheng CW, Yang TC, Li SW, Cheng MH, Wan L, Lin YJ, Lai CH, Lin WY, Kao MC. 2008. Interferon antagonist function of Japanese encephalitis virus NS4A and its interaction with DEAD-box RNA helicase DDX42. *Virus Res* 137(1):49–55.
- Lin RJ, Chang BL, Yu HP, Liao CL, Lin YL. 2006. Blocking of interferon-induced Jak-Stat signaling by Japanese encephalitis virus NS5 through a protein tyrosine phosphatase-mediated mechanism. *J Virol* 80(12):5908–5918.
- Lin RJ, Liao CL, Lin E, Lin YL. 2004. Blocking of the alpha interferon-induced Jak-Stat signaling pathway by Japanese Encephalitis Virus. *J Virol* 78(17):9285–9294.
- Lindenbach BD, Rice CM. 1997. trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication. *J Virol* 71(12):9608–9617.
- Lindenbach BD, Rice CM. 2001. Flaviviridae: The viruses and their replication. In: Knipe DM, Howley PM, eds. *Fields virology*. Philadelphia: Lippincott Williams & Wilkins. pp 991–1041.
- Liu WJ, Chen HB, Wang XJ, Huang H, Khromykh AA. 2004. Analysis of adaptive mutations in kunjin virus replicon RNA reveals a novel role for the flavivirus nonstructural protein NS2A in inhibition of beta interferon promoter-driven transcription. *J Virol* 78(22):12225–12235.
- Liu WJ, Wang XJ, Clark DC, Lobigs M, Hall RA, Khromykh AA. 2006. A single amino acid substitution in the West Nile virus nonstructural protein NS2A disables its ability to inhibit alpha/beta interferon induction and attenuates virus virulence in mice. *J Virol* 80(5):2396–2404.
- Lobigs M, Mullbacher A, Wang Y, Pavy M, Lee E. 2003. Role of type I and type II interferon responses in recovery from infection with an encephalitic flavivirus. *J Gen Virol* 84(Pt 3):567–572.
- Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, Akira S, Gill MA, Garcia-Sastre A, Katze MG, Gale M, Jr. 2008. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. *J Virol* 82(1):335–345.
- Mackenzie JM, Khromykh AA, Jones MK, Westaway EG. 1998. Subcellular localization and some biochemical properties of the flavivirus Kunjin nonstructural proteins NS2A and NS4A. *Virology* 245(2):203–215.
- Mackenzie JM, Khromykh AA, Parton RG. 2007. Cholesterol manipulation by West Nile virus perturbs the cellular immune response. *Cell Host Microbe* 2(4):229–239.
- Mahajan VS, Drake A, Chen J. 2009. Virus-specific host miRNAs: antiviral defenses or promoters of persistent infection? *Trends Immunol* 30(1):1–7.
- Malet H, Egloff MP, Selisko B, Butcher RE, Wright PJ, Roberts M, Gruez A, Sulzenbacher G, Vonnrhein C, Bricogne G, Mackenzie JM, Khromykh AA, Davidson AD, Canard B. 2007. Crystal structure of the RNA polymerase domain of the West Nile virus nonstructural protein 5. *J Biol Chem* 282(14):10678–10689.
- Mashimo T, Lucas M, Simon-Chazottes D, Frenkiel MP, Montagutelli X, Ceccaldi PE, Deubel V, Guenet JL, Despres P. 2002. A nonsense mutation in the gene encoding 2'-5'-oligoadenylate synthetase/L1 isoform is associated with West Nile virus susceptibility in laboratory mice. *Proc Natl Acad Sci USA* 99(17):11311–11316.
- Matsumoto M, Funami K, Oshiumi H, Seya T. 2004. Toll-like receptor 3: a link between toll-like receptor, interferon and viruses. *Microbiol Immunol* 48(3):147–154.
- Medigeshi GR, Hirsch AJ, Streblow DN, Nikolich-Zugich J, Nelson JA. 2008. West Nile virus entry requires cholesterol-rich membrane microdomains and is independent of alphavbeta3 integrin. *J Virol* 82(11):5212–5219.
- Meurs EF, Watanabe Y, Kadereit S, Barber GN, Katze MG, Chong K, Williams BR, Hovanessian AG. 1992. Constitutive expression of human double-stranded RNA-activated p68 kinase in murine cells mediates phosphorylation of eukaryotic initiation factor 2 and partial resistance to encephalomyocarditis virus growth. *J Virol* 66(10):5804–5814.
- Miller JL, deWet BJ, Martinez-Pomares L, Radcliffe CM, Dwek RA, Rudd PM, Gordon S. 2008. The mannose receptor mediates dengue virus infection of macrophages. *PLoS Pathog* 4(2):e17.
- Miller S, Kastner S, Krijnse-Locker J, Buhler S, Bartenschlager R. 2007. The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner. *J Biol Chem* 282(12):8873–8882.
- Miller S, Sparacio S, Bartenschlager R. 2006. Subcellular localization and membrane topology of the Dengue virus type 2 Non-structural protein 4B. *J Biol Chem* 281(13):8854–8863.
- Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. *Nature* 427(6972):313–319.
- Morrey JD, Day CW, Julander JG, Blatt LM, Smee DF, Sidwell RW. 2004. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. *Antivir Chem Chemother* 15(2):101–109.
- Mukhopadhyay S, Kuhn RJ, Rossmann MG. 2005. A structural perspective of the flavivirus life cycle. *Nat Rev Microbiol* 3(1):13–22.
- Munoz-Jordan JL, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin WI, Garcia-Sastre A. 2005. Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. *J Virol* 79(13):8004–8013.
- Munoz-Jordan JL, Sanchez-Burgos GG, Laurent-Rolle M, Garcia-Sastre A. 2003. Inhibition of interferon signaling by dengue virus. *Proc Natl Acad Sci USA* 100:14333–14338.
- Murthy HM, Judge K, DeLucas L, Padmanabhan R. 2000. Crystal structure of Dengue virus NS3 protease in complex with a Bowman-Birk inhibitor: implications for flaviviral polyprotein processing and drug design. *J Mol Biol* 301(4):759–767.
- Park GS, Morris KL, Hallett RG, Bloom ME, Best SM. 2007. Identification of residues critical for the interferon antagonist function of langat virus NS5 reveals a role for the RNA-dependent RNA polymerase domain. *J Virol* 81(13):6936–6946.
- Pedersen IM, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. *Nature* 449(7164):919–922.
- Perelygin AA, Scherbik SV, Zhulin IB, Stockman BM, Li Y, Brinton MA. 2002. Positional cloning of the murine flavivirus resistance gene. *Proc Natl Acad Sci USA* 99(14):9322–9337.
- Platanias LC. 2005. Mechanisms of type-I- and type-II-interferon-mediated signalling. *Nat Rev Immunol* 5(5):375–386.
- Platanias LC, Uddin S, Domanski P, Colamonici OR. 1996. Differences in Interferon α and β signalling. *J Biol Chem* 271(39):23630–23633.
- Purtha WE, Chachu KA, Virgin HWT, Diamond MS. 2008. Early B-cell activation after West Nile virus infection requires alpha/beta interferon but not antigen receptor signaling. *J Virol* 82(22):10964–10974.

- Querec T, Bennouna S, Alkan S, Laouar Y, Gorden K, Flavell R, Akira S, Ahmed R, Pulendran B. 2006. Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. *J Exp Med* 203(2):413–424.
- Rahal JJ, Anderson J, Rosenberg C, Reagan T, Thompson LL. 2004. Effect of interferon- α 2b therapy on St. Louis viral meningoencephalitis: clinical and laboratory results of a pilot study. *J Infect Dis* 190(6):1084–1087.
- Rivieccio MA, Suh HS, Zhao Y, Zhao ML, Chin KC, Lee SC, Brosnan CF. 2006. TLR3 ligation activates an antiviral response in human fetal astrocytes: a role for viperin/cig5. *J Immunol* 177(7):4735–4741.
- Robertson SJ, Mitzel DN, Taylor RT, Best SM, Bloom ME. 2009. Tick-borne flaviviruses: dissecting host immune responses and virus countermeasures. *Immunol Res* 43(1–3):172–186.
- Roosendaal J, Westaway EG, Khromykh A, Mackenzie JM. 2006. Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein. *J Virol* 80(9):4623–4632.
- Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M, Jr. 2008. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. *Nature* 454(7203):523–527.
- Samuel MA, Diamond MS. 2005. Type I IFN protects against lethal West Nile Virus infection by restricting cellular tropism and enhancing neuronal survival. *J Virol* 79(21):13350–13361.
- Samuel MA, Whitby K, Keller BC, Marri A, Barchet W, Williams BRG, Silverman RH, Gale M, Diamond MS. 2006. PKR and RNase L contribute to protection against lethal West Nile virus infection by controlling early viral spread in the periphery and replication in neurons. *J Virol* 80(14):7009–7019.
- Scherbik SV, Paranjape JM, Stockman BM, Silverman RH, Brinton MA. 2006. RNase L plays a role in the antiviral response to West Nile virus. *J Virol* 80(6):2987–2999.
- Scholle F, Mason PW. 2005. West Nile virus replication interferes with both poly(I:C)-induced interferon gene transcription and response to interferon treatment. *Virology* 342(1):77–87.
- Schroder M, Bowie AG. 2005. TLR3 in antiviral immunity: key player or bystander? *Trends Immunol* 26(9):462–468.
- Shresta S, Kyle JL, Snider HM, Basavapatna M, Beatty PR, Harris E. 2004. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. *J Virol* 78(6):2701–2710.
- Solomon T, Dung NM, Wills B, Kneen R, Gainsborough M, Diet TV, Thuy TT, Loan HT, Khanh VC, Vaughn DW, White NJ, Farrar JJ. 2003. Interferon α -2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. *Lancet* 361(9360):821–826.
- Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. 1998. How cells respond to interferons. *Annu Rev Biochem* 67:227–264.
- Stephen EL, Sammons ML, Pannier WL, Baron S, Spertzel RO, Levy HB. 1977. Effect of a nuclease-resistant derivative of polyribonucleosinic-polyribocytidylic acid complex on yellow fever in rhesus monkeys (*Macaca mulatta*). *J Infect Dis* 136(1):122–126.
- Stetson DB, Medzhitov R. 2006. Type I interferons in host defense. *Immunity* 25(3):373–381.
- Takeuchi O, Akira S. 2007. Recognition of viruses by innate immunity. *Immunol Rev* 220:214–224.
- van der Schaar HM, Rust MJ, Chen C, van der Ende-Metselaar H, Wilschut J, Zhuang X, Smit JM. 2008. Dissecting the cell entry pathway of dengue virus by single-particle tracking in living cells. *PLoS Pathog* 4(12):e1000244.
- van der Schaar HM, Rust MJ, Waarts BL, van der Ende-Metselaar H, Kuhn RJ, Wilschut J, Zhuang X, Smit JM. 2007. Characterization of the early events in dengue virus cell entry by biochemical assays and single-virus tracking. *J Virol* 81(21):12019–12028.
- Wang JP, Liu P, Latz E, Golenbock DT, Finberg RW, Libraty DH. 2006. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. *J Immunol* 177(10):7114–7121.
- Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, Flavell RA. 2004. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. *Nat Med* 10(12):1366–1373.
- Wang X, Hinson ER, Cresswell P. 2007. The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts. *Cell Host Microbe* 2(2):96–105.
- Werme K, Wigerius M, Johansson M. 2008. Tick-borne encephalitis virus NS5 associates with membrane protein scribble and impairs interferon-stimulated JAK-STAT signalling. *Cell Microbiol* 10(3):696–712.
- Wilson JR, de Sessions PF, Leon MA, Scholle F. 2008. West Nile virus nonstructural protein 1 inhibits TLR3 signal transduction. *J Virol* 82(17):8262–8271.
- Xu T, Sampath A, Chao A, Wen D, Nanao M, Chene P, Vasudevan SG, Lescar J. 2005. Structure of the Dengue virus helicase/nucleoside triphosphatase catalytic domain at a resolution of 2.4 Å. *J Virol* 79(16):10278–10288.
- Yap TL, Xu T, Chen YL, Malet H, Egloff MP, Canard B, Vasudevan SG, Lescar J. 2007. Crystal structure of the dengue virus RNA-dependent RNA polymerase catalytic domain at 1.85-angstrom resolution. *J Virol* 81(9):4753–4765.
- Yusof R, Clum S, Wetzel M, Murthy HM, Padmanabhan R. 2000. Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids *in vitro*. *J Biol Chem* 275(14):9963–9999.
- Zhang Y, Burke CW, Ryman KD, Klimstra WB. 2007. Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. *J Virol* 81(20):11246–11255.
- Zhou A, Hassel BA, Silverman RH. 1993. Expression cloning of 2-5A-dependent RNAase: a uniquely regulated mediator of interferon action. *Cell* 72(5):753–765.
- Zhou A, Paranjape J, Brown TL, Nie H, Naik S, Dong B, Chang A, Trapp B, Fairchild R, Colmenares C, Silverman RH. 1997. Interferon action and apoptosis are defective in mice devoid of 2',5'-oligoadenylate-dependent RNase L. *EMBO J* 16(21):6355–6363.

Address correspondence to:

Dr. Michael S. Diamond
Departments of Medicine,

Molecular Microbiology, and Pathology and Immunology
Washington University School of Medicine
660 South Euclid Avenue, Box 8051
St. Louis, MO 63110

E-mail: diamond@borcim.wustl.edu

Received 29 June 2009/Accepted 29 June 2009